CrossBridge Bio develops antibody-drug conjugates (ADCs) using proprietary enzymatically cleavable linkers and microbial transglutaminase for precise drug conjugation, enhancing stability and targeted release within cancer cells. This technology addresses the challenges of premature payload release and off-target effects, aiming to improve the efficacy and safety profiles of cancer therapeutics.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional antibody-drug conjugates (ADCs) often suffer from premature payload release, leading to off-target toxicities and reduced efficacy in cancer treatment. Existing linkers may lack stability in circulation, while conjugation methods can result in heterogeneous ADC populations with variable drug-to-antibody ratios (DAR).
Solution
CrossBridge Bio is developing next-generation ADC therapeutics using proprietary enzymatically cleavable linkers and microbial transglutaminase for precise drug conjugation. Their EGCit (GluGlyCit) linker enhances stability against proteases, minimizing premature payload release and off-target effects, while ensuring efficient drug release within targeted cancer cells. The enzymatic conjugation technology enables the integration of multi-arm linkers into human IgG1 at specific locations, resulting in homogenous ADCs with controlled DAR. This approach allows for the creation of dual-payload ADCs, offering synergistic therapeutic effects with simplified manufacturing.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel cancer therapeutics, particularly those specializing in antibody-drug conjugates and targeted drug delivery.
Features
- EGCit (GluGlyCit) enzymatically cleavable linker for enhanced stability and reduced off-target effects
- Microbial transglutaminase (mTG)-mediated enzymatic conjugation for site-specific and controlled DAR
- Capability to develop dual-payload ADCs for synergistic therapeutic effects
- Homogeneous ADC production for consistent efficacy and safety profiles
- Synergistic antibody-payload pairings for optimized therapeutic outcomes
- CBB-120, a TROP-2 ADC for solid tumors, as a lead candidate